Literature DB >> 18001715

Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome.

Baris Ata1, Kayhan Yakin, Cengiz Alatas, Bulent Urman.   

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of dual renin-angiotensin system (RAS) blockage together with total embryo cryopreservation for prevention of ovarian hyperstimulation syndrome (OHSS) in overstimulated patients undergoing IVF.
DESIGN: Retrospective case series.
SETTING: A private tertiary care hospital assisted reproduction program. PATIENT(S): Ten women at high risk for OHSS (mean E(2) level 9401 +/- 585 pg/mL on the day of hCG administration). INTERVENTION(S): Cancellation of ET and dual RAS blockage with an angiotensin receptor blocker (candesartan cilexetil) and an angiotensin-converting enzyme inhibitor (enalapril) starting from day 1 after oocyte retrieval. Embryos were cryopreserved and transferred in subsequent cycles. MAIN OUTCOME MEASURE(S): Development of OHSS and pregnancy and live birth rates after frozen-thawed ETs. RESULT(S): While eight women did not develop OHSS, two women (20%) developed severe OHSS requiring hospitalization. Subsequent frozen-thawed ETs resulted in an 80% clinical pregnancy rate and 40% live birth rate. CONCLUSION(S): Dual RAS blockage with total embryo cryopreservation is a relatively new strategy that was proposed for use in patients at high risk for OHSS. It should be stressed that complete elimination of the syndrome is not possible with this treatment. Subsequent pregnancy rates with the transfer of frozen-thawed embryos are high.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001715     DOI: 10.1016/j.fertnstert.2007.07.1309

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

2.  Failure of fertility therapy and subsequent adverse cardiovascular events.

Authors:  Jacob A Udell; Hong Lu; Donald A Redelmeier
Journal:  CMAJ       Date:  2017-03-13       Impact factor: 8.262

3.  THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN IN VITRO FERTILIZATION PROCEDURE.

Authors:  M Surcel; M Surcel; C Zlatescu-Marton; R Micu; G I Nemeti; D D Axente; C Mirza; I Neamtiu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

4.  Correlation between steroid hormonal levels and cardiac function in women during controlled ovarian hyperstimulation.

Authors:  Yiran Li; Xiuhua Sun; Lili Zang; Quan Zhang; Jichun Li; Shuhua Zou
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

5.  Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome.

Authors:  Nikita Naredi; Sandeep Karunakaran
Journal:  J Hum Reprod Sci       Date:  2013-10

Review 6.  Involvement of ACE2/Ang-(1-7)/MAS1 Axis in the Regulation of Ovarian Function in Mammals.

Authors:  Kamila Domińska
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

7.  Effect and Relationship of Seasons on the High Risk of Ovarian Hyperstimulation Syndrome After Oocyte Retrieval in Patients With Polycystic Ovary Syndrome.

Authors:  Yurong Cao; Hao Shi; Yue Ma; Linna Ma; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

Review 8.  Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention.

Authors:  Petal Elder; Garima Sharma; Martha Gulati; Erin D Michos
Journal:  Am J Prev Cardiol       Date:  2020-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.